Company intelligence / Profile preview
Zentalis Pharmaceuticals
New York, New York, United Stateszentalis.com ↗
- Ownership
- Public · ZNTL
- Development stage
- Phase 2
01
Overview
Lead candidate azenosertib (WEE1 inhibitor) has shown anti-tumor activity as a single agent across multiple tumor types and in combination with several chemotherapy backbones. The company is exploring enrichment strategies targeting tumors of high genomic instability.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesProtein degraders
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $121.7M
- Total revenue
- $0
- Enterprise value
- $-15.2M
Beyond the preview
Go deeper on Zentalis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zentalis Pharmaceuticals.